Jooss Karin 4

What Happened Karin Jooss, a non‑employee director of Fate Therapeutics (FATE), was granted a derivative award on June 12, 2026: an option covering 87,900 shares reported with an acquisition price of $0.00. This was an equity grant (award), not a market purchase or sale — the filing treats it as a stock option award under the company’s director compensation policy.

Key Details

• Transaction date: June 12, 2026; Form 4 filed June 15, 2026.
• Amount: 87,900 derivative shares (option grant); acquisition price shown as $0.00.
• Shares owned after transaction: not specified in the provided filing summary.
• Footnote F1: Grant made under the Issuer’s Amended and Restated Non‑Employee Director Compensation Policy (annual equity grants to non‑employee directors).
• Footnote F2: Vesting — the option vests and becomes exercisable on the earlier of (i) June 12, 2027 or (ii) the Issuer’s 2027 Annual Meeting, contingent on continued board service.
• Transaction type: A = Award/Grant (derivative). No 10b5‑1 plan, tax withholding, or late‑filing flag noted in the provided data.

Context This filing reports an option grant, not an immediate acquisition of common shares. Options give the holder the right to buy shares in the future subject to vesting and exercise terms; they are commonly used to compensate non‑employee directors and do not alone indicate buying or selling intent. For full details on exercise price, expiration and other terms, review the complete Form 4 filing and related company disclosures.